With the release of its 2009 InterQual Criteria and CareEnhance Review Manager 8.0 software, McKesson is offering molecular and genetic diagnostics criteria for clients so that they could improve the quality of care for patients.
Combined with the option for customers to access the criteria through McKesson’s recently launched auto authorization capability, the software seeks to increase the value of the content for users. McKesson’s auto authorization, a hosted, Web-based offering, automates the entire authorization process, from the initial request all the way through final authorization.
Through its InterQual Molecular Diagnostics Criteria, McKesson is providing a comprehensive set of criteria to support decision-making for molecular diagnostic tests. Specifically, it guides health care organizations in determining test appropriateness based on clinical evidence, covering over 225 tests that comprise approximately 85% of the costs.
A new question and answer format offers service recommendations that include alternative and concurrent tests. Furthermore, users can conduct reviews and act on information. Also, pop-up notes and clinical evidence summaries drive evidence-based medicine to the point of decision-making with more efficiency. The content is available in McKesson’s CareEnhance Review Manager solution, as well as the Advanced Diagnostics Management solution auto authorization capability.
